Cynomolgus IGFBP4 Protein (His Tag)

Sino Biological Inc. liefert Cynomolgus IGFBP4 Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Cynomolgus IGFBP4 Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/IGFBP4-Protein-g-10279.html

Produkt-Information von IGFBP4 Protein

QC Testing von IGFBP4 Protein

Purity	> 80 % as determined by SDS-PAGE	SDS-PAGE: IGFBP4 protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Asp 22
Molecular Mass	The recombinant heterodimer of cynomolgus IGFBP4 comprises 248 amino acids and has a calculated molecular mass of 27.4 KDa. The apparent molecular mass of the protein is approximately 33-36 KDa respectively in SDS-PAGE.
Formulation	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von IGFBP4 Protein

Verwandte Produkte & Themen von IGFBP4 Protein

Cancer>>Growth Factor & Receptor>>IGF System>>IGFBP4

Beschreibung von IGFBP4 Protein

Insulin-like growth factor-binding proteins (IGFBPs) control bioavailability, activity, and distribution of insulin-like growth factor (IGF) through high-affinity IGFBP/IGF complexes. Six high-affinity IGF-binding proteins (IGFBP-1 to -6) have been identified, and IGFBP4, the smallest IGFBP expressed by a wide range of cell types, exists in both non-glycosylated and N-glycosylated forms in all biological fluids. Structurally consisting of an IGFBP domain and a thyroglobulin type-I domain, IGFBP4 binds IGF-I and IGF-II with similar affinities as a transport protein and modulates their biological effects. Increasing evidences indicate that IGFBP4 inhibits IGF-induced cellular growth both in vitro and in vivo. As an important member of the IGF system, IGFBP4 is involved in a wide range of biological processes including reproductive physiology, bone formation, renal pathophysiology and carcinomas.

References

1. Durai R. et al., 2006, Int J Oncol. 28: 1317-25.
2. Sitar T. et al., 2006, Proc Natl Acad Sci. 103: 13028-33.
3. Zhou R. et al., 2003, J Endocrinol. 178: 177-93.
4. Zhou J. et al., 2003, Biol Reprod. 69: 22-9.